Anticoagulation with prostaglandins during extracorporeal circulation

Wiener Klinische Wochenschrift

Volumn 111, Issue 4, 1999, Pages 129-140

  Kozek Langenecker, Sibylle A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticoagulation; Extracorporeal circulation; Prostacyclin; Prostaglandin E'1

Indexed keywords

HEPARIN; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E1; PROSTAGLANDIN INHIBITOR;

ABDOMINAL PAIN; ANTICOAGULATION; BLEEDING; CARDIOPULMONARY BYPASS; CELL PROTECTION; EXTRACORPOREAL CIRCULATION; FIBRIN FORMATION; HEADACHE; HEART ASSIST DEVICE; HEPARINIZATION; HUMAN; NAUSEA; PATHOPHYSIOLOGY; PROSTAGLANDIN RELEASE; RESTLESSNESS; REVIEW; THROMBOCYTE FUNCTION; VOMITING;

ANTICOAGULANTS; DRUG THERAPY, COMBINATION; EXTRACORPOREAL CIRCULATION; HEPARIN; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDINS; TREATMENT OUTCOME;

EID: 0033605253     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Salzman E, Merrill E, Kent K (1994) Interaction of blood with artificial surfaces. In: Colman R, Hirsh J, Marder V, Salzman E (eds) Hemostasis and thrombosis. Basic principles and clinical practice. JB Lippincott, Philadelphia, pp 1469-1484
2. Vroman L, Adams A, Klings M (1971) Interactions among human blood proteins at interfaces. Fed Proc 30: 1494-1502
3. Salzman E, Lindon J, McManama G, Ware J (1987) Role of fibrinogen in activation of platelets by artificial surfaces. Ann NY Acad Sci 516: 184-195
4. Baumgartner H, Muggli R, Tschopp T (1976) Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb Diath Haemorrh 35: 124-138
5. Khuri S, Wolfe J, Josa M, Axford T, Szymanski I, Assousa S, Ragno G, Patel M, Siverman A, Park M, Valeri C (1992) Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 104: 94-107
6. Harker L, Slichter S (1972) Platelet and fibrinogen consumption in man. N Engl J Med 287: 999-1005
7. Speiser W, Wojta J, Korninger C, Kirchheimer J, Zazgornik J, Binder B (1987) Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis. Kidney Int 32: 280-283
8. Wachtfogel Y, Kucich U, Hack C, Gluszko P, Niewiarowski S, Colman R, Edmunds LJ (1993) Aprotinin inhibits the contact, neutrophil, and platelet activation system during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106: 1-10
9. Hirsh J, Fuster V (1994) Guide to anticoagulant therapy. Part 1. Circulation 89: 1449-1468
10. Nowak G (1996) Gerinnungsaktivierung im extrakorporalen Kreislauf. Wien Klin Wochenschr 108: 9-14
11. Chen J, Karlber E, Sylven C (1992) Heparin enhances platelet aggregation irrespective of anticoagulation with citrate or with hirudin. Thromb Res 67: 253-262
12. Storck J, Hoellger N, Zimmermann R (1994) The influence of heparin and protamine sulfate on platelet ADP and platelet factor 4 release and the expression of glycoprotein IIb/IIIa. Haemostasis 24: 358-363
13. Winchester J, Forbes C, Courtnery J, Reavey M, Prentice C (1977) Effect of sulphine pyrazone and aspirin on platelet adhesion to activated charcoal and hemodialysis membranes. Thromb Res 11: 443-451
14. Lindsay R, Ferguson D, Prentice C, Burton J, McNicol G (1972) Reduction of thrombus formation on dialyser membranes by aspirin and RA 233. Lancet ii: 1287-1290
15. Woods H, Ash G, Weston M (1978) Prostacyclin can replace heparin in haemodialysis in dogs. Lancet ii: 1075-1077
16. 2 on platelet aggregation in different species. Prostaglandins 16: 373-388
17. Schrör K, Smith E (1990) Dictionary of prostaglandins and related compounds. Medikon Verlag, München
18. 1: molecular mechanisms and therapeutic utility. In: Coller B (ed) Progress in hemostasis and thrombosis. WB Saunders, New York
19. 1 during cardiopulmonary bypass. Eur J Anaesth 8: 129-134
20. 2 and theophyllin on the response of platelets subjected to shear stress. Blood 58: 678-681
21. Gorman R, Bunting S, Miller O (1977) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13: 377-388
22. 1: the endogenous physiological regulator of platelet mediated blood coagulation. Prostaglandins Leukot Fatty Acids 35: 189-195
23. Walsh P (1978) Different requirements for intrinsic factor-Xa forming activity and platelet factor 3 activity and their relationship to platelet aggregation and secretion. Br J Haematol 40: 311-331
24. 1 inhibits platelet decrease after massive blood transfusions during major surgery: influence on coagulation cascade? J Trauma 42: 525-531
25. 1. Anesth Analg 87: 985-988
26. Bunting S, Simmons P, Moncada S (1981) Inhibition of platelet activation by prostacyclin: possible consequences in coagulation and anticoagulation. Thromb Res 21: 89-102
27. Aren C, Feddersen F, Radegran K (1983) Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg 36: 49-54
28. Longmore D, Bennett G, Gueirrara D, Smith H, Bunting S, Moncada S, Reed P, Read N, Vane J (1979) Prostacyclin: a solution to some problems of extracorporeal circulation. Lancet ii: 1002-1005
29. Bennett J, Longmore D, O'Grady J (1981) Use of prostacyclin in cardiopulmonary bypass in man. In: Lewis P, O'Grady J (eds) Clinical pharmacology of prostacyclin. Raven Press, New York, pp 201-208
30. Radegran K, Egberg N, Papaconstantinou C (1981) Effects of prostacyclin during cardiopulmonary bypass in man. Scand J Thorac Cardiovasc Surg 15: 263-268
31. Bunting S, Moncada S (1980) Prostacyclin by preventing platelet activation prolongs activated clotting time in blood and platelet rich plasma and potentiates the anticoagulant effect of heparin. Br J Pharmacol 69: 268-269
32. Turney J, Fewell M, Williams L, Parsons V, Weston M (1980) Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet ii: 219-222
33. Fish K, Sarnquist F, van Steennis C, Mitchell R, Hilberman M, Jamieson S, Linet O, Miller D (1986) A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg 91: 436-442
34. Dibble J, Kalra P, Orchard M, Turney J, Davies J (1988) Prostacyclin and iloprost do not affect action of standard dose heparin on haemostatic function during haemodialysis. Thromb Res 49: 385-392
35. Coppe D, Sobel M, Seamans L, Levine F, Salzman E (1981) Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 81: 274-278
36. Despotis G, JH J, Hogue C, Alsoufiev A, Kater K, Goodnough L, Santoro S, Spitznagel E, Rosenblum M, Lappas D (1995) The impact of heparin concentration and activated clotting time monitoring on blood conservation. J Thorac Cardiovasc Surg 110: 46-54
37. Novacek G, Kapiotis S, Jilma B, Quehenberger P, Michitsch A, Traindl O, Speiser W (1997) Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. Thromb Res 88: 283-290
38. Davenport A, Will E, Davidson A (1993) Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21: 328-338
39. Szczeklik A, Gryglewski R, Nizankowski R, Musial J, Pieton R, Mruk J (1978) Circulatory and anti-platelet effects of intravenous prostacyclin in healthy man. Pharmacol Res Commun 10: 545-556
40. Aren C, Blomstrand C, Wikkelsoe C, Radegran K (1984) Hypotension induced by prostacyclin treatment during cardiopulmonary bypass does not increase the risk of cerebral complications. J Thorac Cardiovasc Surg 88: 748-753
41. 1 in man. Eur J Clin Pharmacol 33: 133-137
42. El-Gatit A, Al-Khaja N, Belboul A, Roberts D, William-Olsson G (1992) Effects of alprostadil infusion during extracorporeal circulation on blood rheology and postoperative blood loss. Vasc Surg 26: 521-528
43. 2): new aspects of an old substance in the treatment of critically ill patients. Intensive Care Med 23: 146-158
44. Aren C, Fedderson K, Radegran K (1984) Effects of prostacyclin infusion on platelets and hemodynamics in coronary bypass surgery. J Thorac Cardiovasc Surg 32: 81-84
45. Schrör K, Ohlendorf R, Darius H (1981) Beneficial effects of a new carbacyclin derivate, ZK36374. in acute myocardial ischemia. J Pharmacol Exp Ther 219: 243-249
46. 2. Naunyn Schmiedebergs Arch Pharmacol 341: 308-315
47. 1: physiological significance and clinical use. Wien Klin Wochenschr 14: 471-477
48. Abe K, Fujino Y, Sakakibara T (1993) The effect of prostaglandin EI during cardiopulmonary bypass on renal function after cardiac surgery. Eur J Clin Pharmacol 45: 217-220
49. Feddersen K, Aren C, Granerus G, Jagenburg R, Radegran K (1985) Effects of prostacyclin infusion on renal function during cardiopulmonary bypass. Ann Thorac Surg 40: 16-19
50. 1 bei Patienten mit terminaler Herzinsuffizienz. Wien Klin Wochenschr 110: 473-478
51. 1 on human platelet function. J Lab Clin Med 109: 184-190
52. Kratzer M, Born G (1985) Simulation of primary haemostasis in vitro. Haemostasis 15: 357-362
53. Langenecker S, Felfernig M, Werba A, Müller C, Chiari A, Zimpfer M (1994) Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 22: 1774-1781
54. Maurin N (1988) The in vitro bleeding time while using a stable prostacyclin analogue during hemodialysis. Artif Kid Dial 11: 243-248
55. 1. Anesthesiology 85: A228
56. Despotis G, Levine V, Filos K, Santoro S, Joist J, Spitznagel E, Goodnough L (1996) Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 85: 1311-1323
57. 1 in intensive care. Facultas, Wien, pp 58-76
58. Boers M, Van den Dungen J, Karliczek G, Brenken U, Van der Heide J, Wildevuur C (1983) Two membrane oxygenators and a bubble: a clinical comparison. Ann Thorac Surg 35: 455-462
59. Nieuwland R, Berckmans R, Rotteveel-Eijkman R, Maquelin K, Roozendaal K, Jansen P, Have K, Eijsman L, Hack E, Sturk A (1997) Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 96: 3534-3541
60. Woodman R, Harker L (1990) Bleeding complications associated with cardiopulmonary bypass. Blood 76: 1680-1697
61. Prondzinsky R, Müller-Werdan U, Pilz G, Witthaut R, Stabenow I, Werdan K, Zerkowski H-R (1997) Systemische Entzündungsreaktionen extrakorporaler Therapieverfahren (II): Der kardiopulmonale Bypass. Wien Klin Wochenschr 109: 346-353
62. Velthuis H, Baufreton D, Jansen P, Thijs C, Hack C, Sturck A, Wildevuur C, Loisance D (1997) Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations. J Thorac Cardiovasc Surg 114: 117-122
63. Ernofson M, Thelin S, Siegbahn A (1997) Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 113: 576-584
64. 1 inhibit monocyte procoagulant activity in vitro. Blood 78: 382-386
65. Despotis G, Filos K, Zoys T, Hogue C, Spitznagel E, Lappas D (1996) Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 82: 13-21
66. Harker L (1986) Bleeding after cardiopulmonary bypass. N Engl J Med 314: 1446-1448
67. 1 on platelet decrease in the heart-lung machine. Haemostasis 2: 294-303
68. Heinrich D, Schleussner E, Wagner W, Sellmann-Richter R, Hehrlein F (1983) Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study. Thromb Res 32: 409-426
69. 1 on platelet loss during in vivo and in vitro extracorporeal circulation with a bubble oxygenator. J Thorac Cardiovasc Surg 77: 119-126
70. Addonizio V, Fisher C, Jenken B, Strauss J, Musial J, Edmunds L (1985) Iloprost (ZK36374), a stable analogue of prostacyclin, preserves platelets during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 89: 926-933
71. Faichney A, Davidson K, Wheatley D, Davidson J, Walker I (1982) Prostacyclin in cardiopulmonary bypass operations. J Thorac Cardiovasc Surg 84: 601-608
72. Walker I, Davidson J, Faichney A, Wheatley D, Davidson K (1981) A double-blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol 49: 415-423
73. Malpass T, Amory D, Harker L, Ive T, Williams D (1984) The effect of prostacyclin infusion on platelet hemostatic function in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 87: 550-555
74. 1α and heparin. Thromb Res 32: 393-408
75. DiSesa V, Huval W, Lelcuk S, Jonas R, Maddi R, Lee-Son S, Shemin R, Collins J, Hechtman H, Cohn L (1984) Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. Ann Thorac Surg 38: 514-519
76. 1 in patients undergoing clinical cardiopulmonary bypass. Ann Thorac Surg 35: 406-414
77. 1-Infusion bei Patienten mit chronisch arterieller Verschlußkrankheit. Wien Klin Wochenschr 100: 477-481
78. 2. J Pharmacol Exp Ther 222: 544-549
79. Kuzniewski M, Sulowicz W, Lisiewicz J (1991) Effects of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients. Int Urol Nephrol 23: 89-96
80. Slogoff S, Girgis K, Keats A (1982) Etiologic factors in neuropsychiatric complications associated with cardiopulmonary bypass. Anesth Analg 61: 903-911
81. 1 in patients before and during cardiopulmonary bypass. Thorac Cardiovasc Surgeon 29: 55-59
82. El-Gatit A, Al-Khaja N, Belboul A, Radegran G, Roberts D (1992) Influence of alprostadil on pulmonary dysfunction after a cardiac operation. Ann Thorac Surg 53: 1018-1022
83. Bolanowski P, Bauer J, Machiedo G, Neville W (1976) Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 73: 221-224
84. 1 prevents increased lung microvasculature permeability during intravascular complement activation in sheep. Circ Res 61: 420-428
85. 2 on cardiopulmonary bypass-induced lung injury. Perfusion 9: 23-33
86. Walenga J, Hoppensteadt D, Fareed J, Pifarre R (1992) Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers. Ann Thorac Surg 53: 844-850
87. Palantianos G, Edmunds H, Cohen D, Stephenson L (1983) Extracorporeal left ventricular assistance with prostacyclin and heparinized centrifugal pump. Ann Thorac Surg 35: 505-515
88. Adrassy K, Ritz E, Bommer J (1987) Effects of hemodialysis on platelets. Contr Nephrol 59: 26-32
89. Lindsay R, Prentice C, Davidson J, Burton J, McNicol G (1972) Hemostatic changes during dialysis associated with thrombus formation in dialysis membranes. Br Med J 4: 454-458
90. Eberst M, Berkowitz L (1994) Hemostasis in renal disease: pathophysiology and management. Am J Med 96: 168-179
91. Schmitt G, Moake J, Rudy C, Vicks S, Hamburger R (1987) Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VIII-related von Willebrand factor during hemodialysis. Am J Med 83: 411-418
92. 2) as sole anticoagulant. Dialysis Transplant 14: 579-580
93. 2, prostacyclin) during high risk hemodialysis preventing further bleeding complications. J Clin Pharmacol 28: 818-825
94. Keogh A, Rylance P, Weston M, Parsons V (1984) Prostacyclin haemodialysis in patients at risk of haemorrhage. Proc Eur Dial Trans Assoc 13: 51-54
95. Smith M, Danviriyasup K, Crow J, Cato A, Park G, Hassid A, Dunn M (1982) Prostacyclin substitution for heparin in longterm hemodialysis. Am J Med 73: 669-678
96. Zusman R, Rubin R, Cato A, Cocchetto D, Crow J, Tolkoff-Rubin N (1981) Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304: 934-939
97. Ozasa H, Suzuki T, Ota K (1995) Effect of oral prostacyclin on microclots in tube lines of a hemodialysis system. Nephron 71: 106-107
98. Hory B, Saint-Miller Y, Perol J (1983) Prostacyclin as the sole antithrombotic agent for acute renal failure hemodialysis. Nephron 33: 71
99. 2) versus heparin in hemodialysis. Trans Am Soc Artif Intern Organs 30: 52-54
100. Caruana R, Smith M, Clyne D, Crow J, Zinn J, Diehl J (1991) Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purif 9: 296-304
101. Rylance R, Gordge M, Ireland H, Lane D, Weston M (1985) Hemodialysis with prostacyclin (epoprostenol) alone. Proc Eur Dial Transplant Assoc 21: 281-286
102. Brierly J, Hutchinson A (1991) Prolongation of filter life in continuous arterio-venous haemodialysis. Intensive Care Med 17: 187-189
103. Maurin N, Ballmann M (1988) Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin. Clin Nephrol 30: 35-41
104. Kuzniewski M, Sulowicz W, Hanicki Z, Kus J, Nowogrodzka-Zagorska M, Kostka-Trabka E, Bieron K, Debinska-Kiec A (1990) Effect of heparin and prostacyclin/heparin infusion on platelet aggregation in hemodialyzed patients. Nephron 56: 174-178
105. Kuzniewski M, Sulowicz W (1992) Influence of prostacyclin infusion on haemodialysis efficiency and blood cells. Int Urol Nephrol 24: 555-563
106. Camici M, Evangelisti L (1986) Prostacyclin and heparin during haemodialysis: comparative effects. Life Support Syst 4: 205-209
107. Spagnuolo P, Bass S, Smith M, Danviriyasup K, Dunn M (1982) Neutrophil adhesiveness during prostacyclin and heparin hemodialysis. Blood 60: 924-929
108. Wachtfogel Y, Kucich U, Greenplate J, Gluszko P, W A, Weinbaum G, Wenger R, Rucinski B, Niewiarowski S, Edmunds L, Colman R (1987) Human neutrophil degranulation during extracorporeal circulation. Blood 69: 324-330
109. Kramar R (1993) Gefäßzugang, Antikoagulation. In: Bergmann H, Löffler W (Hrsg) Hämofiltration, Hämodialyse, Hämapherese. Springer, Berlin Heidelberg New York Tokyo, S 47-57
110. Journois D, Chanu D, Pouard P, Mauriat P, Safran D (1991) Assessment of standard ultrafiltrate production rate using prostacyclin in continuous venovenous hemofiltration. Contr Nephrol 93: 202-204
111. Canaud B, Mion C, Arujo A, N'Guyen Q, Paleyrac G, Hemmendinger S (1988) Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. Nephron 48: 206-212
112. Zobel G, Trop M, Muntean W, Ring E, Gleispach H (1988) Anticoagulation for continuous arteriovenous hernofiltration in children. Blood Purif 6: 90-95
113. Ponikvar R, Kandus A, Buturovic J, Kveder R (1991) Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration. Contr Nephrol 93: 218-220
114. Davenport A, Will E, Davison A (1994) Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 66: 431-437
115. 1 and unfractionated heparin during continuous venovenous hemofiltration. Crit Care Med 26: 1208-1212
116. Despotis G, Levine V, Joist , Joiner-Maier D, Spitznagel E (1997) Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 85: 498-506
117. Langley P, Keays R, Hughes R, Forbes A, Delvos U, Williams R (1990) Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 14: 251-256
118. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen S (1994) Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med 20: 212-215
119. Mellfren K, Friberg L, Hedner T, Mellgren G, Wadenvik H (1995) Blood platelet activation and membrane glycoprotein changes during extracorporeal life support (ECLS). In vitro studies. Int J Artif Organs 18: 315-321
120. Coppe D, Wonders T, Snider M, Salzman E (1979) Preservation of platelet number and function during extracorporeal membrane oxygenation by regional perfusion of prostacyclin. In: Vane J, Berström S (eds) Prostacyclin. Raven Press, New York, pp 371-383
121. 1. Springer, Berlin Heidelberg New York Tokyo, S 171-180
122. Weston M (1983) Prostacyclin and extracorporeal circulation. Br Med Bull 39: 285-288
123. Gimson A, Hughes R, Mellon P, Woods H, Langley P, Canalese J, Williams R, Weston M (1980) Prostacyclin to prevent platelet activation during charcoal hemoperfusion in fulminant hepatic failure. Lancet i: 173-175
124. Bunting S, Moncada S, Vane J, Woods H, Weston M (1979) Prostacyclin improves hemocompatibility during charcoal hemoperfusion. In: Vane J, Berstroem (eds) Prostacyclin. Raven Press, New York, pp 361-369